
Sol-Gel Technologies (SLGL) Stock Forecast & Price Target
Sol-Gel Technologies (SLGL) Analyst Ratings
Bulls say
Sol-Gel Technologies is a dermatology company with a promising pipeline of product candidates, including SGT-610, a topical drug targeting the hedgehog signaling pathway for the treatment of Gorlin syndrome. The release of top-line data from the pivotal Phase 3 trial of SGT-610 is expected to occur in late 2026, with potential FDA approval and launch in 2027 and 2028, respectively. With a potential peak revenue exceeding $300M annually, SGT-610 has the potential to be a significant value driver for the company.
Bears say
Sol-Gel Technologies is facing significant risks to achieving its price objectives, with potential setbacks in key clinical trials such as the failure of SGT-610 pivotal trial in Gorlin syndrome and the inability to secure U.S. regulatory approval for SGT-610. The recent negative results from the topical erlotinib clinical study for SGT-210 in Darier disease and its discontinuation for further development in this indication also add to the risks and may impact the company's valuation in the future. However, the company's plans to continue exploring potential future applications for SGT-210 through small, targeted proof-of-concept studies may provide some potential upside.
This aggregate rating is based on analysts' research of Sol-Gel Technologies and is not a guaranteed prediction by Public.com or investment advice.
Sol-Gel Technologies (SLGL) Analyst Forecast & Price Prediction
Start investing in Sol-Gel Technologies (SLGL)
Order type
Buy in
Order amount
Est. shares
0 shares